Noman Ashraf, MD

Noman Ashraf, MD, discusses notable data seen with T-DXd treatment in previously treated HER2-mutated and -overexpressing non–small cell lung cancer.

Noman Ashraf, MD, discusses ivonescimab vs pembrolizumab as a first-line treatment for PD-L1-positive, advanced non-small cell lung cancer.